Trinity Biotech PLC (NASDAQ:TRIB) Short Interest Down 39.6% in June

Trinity Biotech PLC (NASDAQ:TRIB) saw a significant decline in short interest in June. As of June 15th, there was short interest totaling 144,829 shares, a decline of 39.6% from the May 31st total of 239,691 shares. Based on an average daily trading volume, of 145,980 shares, the short-interest ratio is currently 1.0 days. Currently, 4.4% of the shares of the stock are short sold.

Institutional Trading of Trinity Biotech

Large investors have recently bought and sold shares of the business. Perceptive Advisors LLC bought a new position in Trinity Biotech in the second quarter valued at about $1,164,000. Hunter Associates Investment Management LLC lifted its holdings in shares of Trinity Biotech by 8.1% in the fourth quarter. Hunter Associates Investment Management LLC now owns 526,610 shares of the company’s stock worth $417,000 after acquiring an additional 39,500 shares during the last quarter. Yorkville Advisors Global LP acquired a new stake in shares of Trinity Biotech in the 1st quarter valued at approximately $122,000. Williams & Novak LLC grew its holdings in shares of Trinity Biotech by 677.5% during the 4th quarter. Williams & Novak LLC now owns 93,300 shares of the company’s stock valued at $74,000 after purchasing an additional 81,300 shares during the last quarter. Finally, Citadel Advisors LLC grew its holdings in shares of Trinity Biotech by 196.1% during the 3rd quarter. Citadel Advisors LLC now owns 39,384 shares of the company’s stock valued at $41,000 after purchasing an additional 26,084 shares during the last quarter. 78.97% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Separately, Weiss Ratings downgraded Trinity Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 8th. One analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Trinity Biotech has an average rating of “Reduce”.

Trinity Biotech Trading Up 5.5%

NASDAQ TRIB opened at $0.38 on Friday. The firm’s 50 day simple moving average is $0.59 and its 200 day simple moving average is $0.70. Trinity Biotech has a 1 year low of $0.31 and a 1 year high of $3.44.

Trinity Biotech (NASDAQ:TRIB) last announced its quarterly earnings data on Tuesday, June 16th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.08. The firm had revenue of $10.85 million for the quarter, compared to analyst estimates of $10.68 million.

About Trinity Biotech

Trinity Biotech plc is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point‐of‐care environments.

The company’s product portfolio includes a comprehensive array of assays and instrumentation.